- Trent Ltd posted a 25.8% YoY rise in standalone net profit to Rs 532 crore
- Revenue growth stayed below 20% for the fifth consecutive quarter at Trent Ltd
- Emcure Pharmaceuticals' Q1 net profit rose 42% to Rs 294 crore YoY
Trent Ltd. reported a stronger-than-expected first quarter, with profit and operating performance beating Street estimates even as revenue growth remained below the 20% mark for the fifth consecutive quarter.
The Tata Group retailer posted a 25.8% year-on-year rise in standalone net profit to Rs 532 crore, ahead of analysts' estimate of Rs 501 crore.
Emcure Pharmaceuticals Q1 Results - Cons, YoY
- Net profit up 42% at Rs 294 crore vs Rs 207 crore YoY
- Revenue up 22.8% at Rs 2,580 crore vs Rs 2,101 crore YoY
- EBITDA up 27.8% at Rs 533 crore vs Rs 417 crore YoY
- EBITDA margin at 20.7% vs 19.8% YoY
Revenue from operations increased 18.5% to Rs 5,666 crore from Rs 4,781 crore a year ago, while EBITDA jumped 32.5% to Rs 1,110 crore, comfortably beating the Street estimate of Rs 1,010 crore. The EBITDA margin expanded to 19.6% from 17.5% a year earlier.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.